Protecting Democracy [1]

American democracy is in jeopardy, from the disastrous Citizens United ruling that flooded our politics with corporate cash to the immoral assault on voting rights. We work every day to defend against these threats and advance bold reforms.

Tell Congress: Pass the Protecting Our Democracy Act

Add Your Name

Generative Artificial Intelligence and Threats to Democracy

Protecting Elected Officials from Threats
Making Government Work [2]

The U.S. government should work for the public, not corporations or industry. It should safeguard consumers, workers and the environment, and be funded well enough to do so. The budget process must not be obstructed by partisanship.

Get Corporate Money Out of Politics

Sign the Petition

It’s Time to Cut the Bloated Pentagon Budget to Fund People, Not Military Contractors

Ensuring Public Money Does Not Go To Private Equity
Consumer & Worker Safeguards [3]

Every day, Big Banks, Big Polluters, and Big Tech companies are threatening our economy, our environment, and our democracy – sacrificing Main Street Americans and our families on the altar of corporate profits. Public Citizen advocates for ordinary people by taking on corporate interests and their cronies in government.

Don’t Let Big Tech Write Our Digital Privacy Laws

Sign Now

Public Citizen Calls on Presidential Candidates, Parties to Pledge Not to Use Dangerous, Manipulative Deepfakes

Within Reach: Banker Pay Reform
Safe & Affordable Drugs & Devices [4]

Prescription drugs are unaffordable and new drugs and devices often are approved without being proven safe and effective. Public Citizen challenges Big Pharma, device manufacturers and federal regulators to make drugs and medical devices safe, effective and accessible to all.

Tell President Biden: Make Meds Affordable

SEND AN EMAIL
Health Care [5]

Health care in the U.S. leaves too many people out, costs too much and doesn’t meet acceptable standards of quality. Much of the care that we get is unaffordable, unnecessary or harmful. Public Citizen advocates Medicare for All, stronger oversight of dangerous doctors and safe clinical trials.

Win Medicare for All

Take Action Now

Report: Ranking of the Rate of State Medical Boards’ Serious Disciplinary Actions, 2019-2021

Petition to the FDA to Strengthen Safety Warning for Botox and Related Drugs and Remove Misleading Claims From Botox/Botox Cosmetic Labeling
Globalization & Trade [6]

Global Trade Watch’s mission is to ensure that in this era of globalization, a majority have the opportunity to enjoy economic security, a healthy environment, safe food, medicines and products, access to quality affordable services such as health care and the exercise of democratic decision-making about the matters that affect our lives. Global Trade Watch has led the fight against corporate-rigged “trade” agreements that provide special powers for Big Pharma to raise medicine prices, promote the outsourcing of jobs to low-wage countries and undermine the food safety and other safeguards on which our families rely. For decades, we have fought for progressive alternatives that benefit people and the planet.

President Biden: No Secrecy in Indo-Pacific Trade Talks

Take Action

Climate Peace Clause Needed to Stop Trade Attacks on Climate Policies

Big Tech’s “Digital Trade” Power-Grab
Climate & Energy [7]

The climate crisis is the challenge of our time. We can fix it with solutions that will make us healthier and more economically secure. We must act quickly to make our economy run on renewable power — and ensure that disadvantaged families and displaced workers share equitably in the new economy. We also must fight the corrupting power of fossil fuel companies and ensure that energy regulators are effective and publicly accountable.

Tell Toyota: Go all-in on EVs

Add Your Name

Climate Roadmap for U.S. Financial Regulation

Toyota’s Troubling Electric Vehicle Track Record
Justice & the Courts [8]

Litigation can remedy or deter wrongdoing, impact policy and meaningfully slow abuses of power. Whether suing on behalf of our members to ensure the honest functioning of government, or representing individual consumers seeking redress in court, our litigation draws on our expertise in administrative law, constitutional law, and government transparency.

Subscribe to the Supreme Court Conference Preview

Sign Up

Johnson & Johnson and the Medicines Patent Pool

Johnson & Johnson formerly refused to negotiate any licensing agreements with the Medicines Patent Pool on December 19th, 2011.

Below, find a brief chronology of Johnson & Johnson’s relationship with the Medicines Patent Pool including letters and statements leading up to J&J’s latest refusal:

December 21, 2011 – MSF criticizes Johnson & Johnson for turning its back on PLHIV and refusing to join the MPP (links to doctorswithoutborders.org)

December 19, 2011 – MPP releases statement on Johnson & Johnson’s refusal to negotiate (links to medicinespatentpool.org)

December 19, 2011 – Johnson & Johnson sends letter to MPP refusing to participate in negotiations (links to keionline.org)

December 15, 2011 – Johnson & Johnson responds to Public Citizen’s letter

December 15, 2011 – MSF organizes letter campaign requesting Johnson & Johnson to enter negotiations with the MPP (links to doctorswithoutborders.org)

December 7, 2011 – Public Citizen sends Tibotec / Johnson & Johnson a letter urging them to negotiate with the MPP

April 25, 2011 – MSF press release on Johnson & Johnson’s refusal to participate in the MPP (links to doctorswithoutborders.org)

April 25, 2011 – MSF writes Johnson & Johnson on their failure to license to the MPP (links to doctorswithoutborders.org)

January 31, 2011 – Johnson & Johnson declines the MPP’s invitation to negotiations (links to medicinespatentpool.org)

January 28, 2011 – MSF criticizes Johnson & Johnson / Tibotec voluntary licensing arrangements (links to doctorswithoutborders.org)

December 1, 2010 – The MPP writes Johnson & Johnson, inviting them to participate in negotiations (links to medicinespatentpool.org)

Fall 2009-Fall 2010 – MSF writes Johnson & Johnson twice asking them to negotiate with the MPP